Breakthrough Study on Nexpowder™ in Gastroenterology
Nextbiomedical has made significant strides in the medical field with the publication of its groundbreaking study on Nexpowder™, a proprietary hemostatic powder, in the esteemed gastroenterology journal,
GUT. This journal holds an impact factor of 23, indicating the high caliber of research it publishes. The study presents compelling evidence that Nexpowder™ can significantly lower the chances of rebleeding following successful endoscopic hemostasis in patients suffering from
non-variceal upper gastrointestinal bleeding (NVUGIB).
The Study Design
Conducted across three leading university hospitals in
South Korea, this large-scale randomized controlled trial evaluated 341 patients who had achieved primary hemostasis through standard therapy. These patients were divided into two groups: one group received standard therapy alone, while the other had standard therapy supplemented with Nexpowder™.
Key Findings
Among the results, the study reported a stark contrast in the rates of rebleeding:
- - 72-hour rebleeding rate: 2.9% for the Nexpowder™ group versus 11.3% for the control group (p = 0.005)
- - 30-day cumulative rebleeding rate: 7.0% compared to 18.8% in the control (p = 0.004)
- - Ulcer subgroup (3-day rebleeding): 3.0% versus 12.0% (p = 0.004)
These results indicate that the addition of Nexpowder™ can drastically improve patient outcomes when managing NVUGIB.
Mechanism of Action
Nexpowder™ functions through its unique ability to adhere to bleeding lesions, forming a protective gel upon contact with moisture. This gel not only provides a shield over the wound but also plays a vital role in preventing both early and delayed rebleeding, particularly in challenging scenarios, such as those involving peptic ulcers.
The traditional approach to treating upper GI bleeding often involves the administration of proton pump inhibitors (PPIs), which work to suppress gastric acid production. However, this study represents the first instance demonstrating a reduction in gastrointestinal rebleeding since the inclusion of PPIs in clinical guidelines. Moreover, it positions Nexpowder™ as a potentially transformative component in rebleeding prevention protocols post-endoscopic treatment.
Implications for Clinical Practice
According to the Chief Technology Officer of Nextbiomedical, "Nexpowder™ stands as a first-in-class solution for rebleeding prevention. The statistically significant outcomes from our well-conducted multicenter randomized controlled trial showcase a clinically meaningful advantage over current treatment options. These results not only enhance the scientific basis of our product but also suggest a potential shift in the management of upper GI bleeding. We anticipate that these findings will foster broader global usage and guide future guideline updates."
Currently, Nexpowder™ is available in both the United States and Europe, facilitated through a global partnership with
Medtronic. To ensure ongoing support for the wider application of Nexpowder™, Nextbiomedical is actively enhancing its post-market clinical program in various key regions.
In conclusion, the publication of this landmark study marks a significant advancement in gastroenterology and underscores Nextbiomedical's commitment to improving patient outcomes through innovative medical solutions. As healthcare evolves, the incorporation of groundbreaking products like Nexpowder™ could redefine treatment paths for patients at risk of gastrointestinal bleeding.